Information  X 
Enter a valid email address

Company Name matching 'Prothena Corporation plc'

Date
Time Source
Company
Announcement
02 Aug 2022 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 9:05 pm GNW   Prothena Corporation plc Prothena to Report Second Quarter 2022 Financial Results on August 8th
01 Jul 2022 9:16 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2022 9:05 pm GNW   Prothena Corporation plc Prothena to Participate in Jefferies Healthcare Conference
05 May 2022 9:05 pm GNW   Prothena Corporation plc Prothena Reports First Quarter 2022 Financial Results and Business Highlights
28 Apr 2022 9:05 pm GNW   Prothena Corporation plc Prothena to Report First Quarter 2022 Financial Results on May 5th
26 Apr 2022 1:30 pm GNW   Prothena Corporation plc Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
28 Mar 2022 1:30 pm GNW   Prothena Corporation plc Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
21 Mar 2022 8:05 pm GNW   Prothena Corporation plc Prothena to Participate in Stifel 2022 Virtual CNS Days
16 Mar 2022 9:30 am GNW   Prothena Corporation plc Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
17 Feb 2022 9:05 pm GNW   Prothena Corporation plc Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
10 Feb 2022 9:05 pm GNW   Prothena Corporation plc Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
29 Nov 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Participate in JMP Securities Hematology and Oncology Summit
04 Nov 2021 8:05 pm GNW   Prothena Corporation plc Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
28 Oct 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Report Third Quarter 2021 Financial Results on November 4th
01 Oct 2021 9:30 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  9:05 pm GNW   Prothena Corporation plc Prothena Announces Executive Appointments
03 Sep 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Participate in Upcoming September Healthcare Conferences
05 Aug 2021 9:05 pm GNW   Prothena Corporation plc Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
29 Jul 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Report Second Quarter 2021 Financial Results on August 5th
26 Jul 2021 2:00 pm GNW   Prothena Corporation plc Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
20 Jul 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
12 Jul 2021 12:00 pm GNW   Prothena Corporation plc Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
24 Jun 2021 1:30 pm GNW   Prothena Corporation plc Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
10 Jun 2021 7:18 pm GNW   Prothena Corporation plc Prothena to Participate in JMP Securities Life Sciences Conference on June 16
20 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
11 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
10 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
07 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Report First Quarter 2021 Financial Results on May 11th
18 Apr 2021 8:05 pm GNW   Prothena Corporation plc Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
15 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
07 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
24 Mar 2021 12:00 pm GNW   Prothena Corporation plc Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
23 Mar 2021 8:29 pm GNW   Prothena Corporation plc Prothena Announces Proposed Offering of Ordinary Shares
08 Mar 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
24 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
11 Feb 2021 1:00 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
05 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
01 Feb 2021 9:15 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
09 Dec 2020 1:00 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
04 Dec 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
  1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
28 Oct 2020 8:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Third Quarter 2020 Financial Results on November 4
20 Oct 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
02 Oct 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15 Sep 2020 1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
11 Sep 2020 1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
08 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
03 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
02 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Aug 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
05 Aug 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
30 Jul 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Second Quarter 2020 Financial Results on August 6
27 May 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
06 May 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance


Company Announcements Archive »


a d v e r t i s e m e n t